Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma
BACKGROUND Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy...
Gespeichert in:
| Veröffentlicht in: | Archives of ophthalmology (1960) 2003-08, Vol.121 (8), p.1120-1124 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1124 |
|---|---|
| container_issue | 8 |
| container_start_page | 1120 |
| container_title | Archives of ophthalmology (1960) |
| container_volume | 121 |
| creator | Mulvihill, Alan Budning, Andrew Jay, Venita Vandenhoven, Cynthia Heon, Elise Gallie, Brenda L Chan, Helen S. L |
| description | BACKGROUND Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy. METHODS We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin. During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after tumor control with ocular motility at diagnosis. Eyes subsequently enucleated because of treatment failure (n = 4) were examined histologically. RESULTS Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy. Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis. The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult. Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.Arch Ophthalmol. 2003;121:1120-1124
--> |
| doi_str_mv | 10.1001/archopht.121.8.1120 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_231965428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>415558</ama_id><sourcerecordid>405723461</sourcerecordid><originalsourceid>FETCH-LOGICAL-a516t-441efb0528bb758f744589d043f431ce10ec133f4c7e4ea7165ada16fa2fd28e3</originalsourceid><addsrcrecordid>eNpFkFlLxDAQgIMouh4_QAQpgo9dMzm66aMsXqAIHs9h2k1spW1qkj7svzeyqz7N9c0MfIScAZ0DpXCFvm7c2MQ5MJirOQCjO2QGkqucFxR2yYxSyvOylPSAHIbwmcoCaLlPDoCVwApVzsjLcz116LMnF9uujets2eDwYUJ2baPx2etURTO4IVuir9zYYWxT3pjexcZ4HNeZdT57Mantqg5DdD0ekz2LXTAn23hE3m9v3pb3-ePz3cPy-jFHCUXMhQBjKyqZqqqFVHYhhFTligpuBYfaADU18FTUCyMMLqCQuEIoLDK7YsrwI3KxuTt69zWZEPWnm_yQXmrGoSykYCpBfAPV3oXgjdWjb3v0aw1U_2jUvxp10qiV_tGYts63p6eqN6v_na23BFxuAQw1dtbjULfhn5O0oBwgcacbDnv8mwqQUir-DWsVhaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>231965428</pqid></control><display><type>article</type><title>Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mulvihill, Alan ; Budning, Andrew ; Jay, Venita ; Vandenhoven, Cynthia ; Heon, Elise ; Gallie, Brenda L ; Chan, Helen S. L</creator><creatorcontrib>Mulvihill, Alan ; Budning, Andrew ; Jay, Venita ; Vandenhoven, Cynthia ; Heon, Elise ; Gallie, Brenda L ; Chan, Helen S. L</creatorcontrib><description>BACKGROUND Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy. METHODS We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin. During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after tumor control with ocular motility at diagnosis. Eyes subsequently enucleated because of treatment failure (n = 4) were examined histologically. RESULTS Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy. Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis. The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult. Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.Arch Ophthalmol. 2003;121:1120-1124
--></description><identifier>ISSN: 0003-9950</identifier><identifier>ISSN: 2168-6165</identifier><identifier>EISSN: 1538-3601</identifier><identifier>EISSN: 2168-6173</identifier><identifier>DOI: 10.1001/archopht.121.8.1120</identifier><identifier>PMID: 12912689</identifier><language>eng</language><publisher>Chicago, IL: American Medical Association</publisher><subject>Adolescent ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Biological and medical sciences ; Carboplatin - administration & dosage ; Carboplatin - adverse effects ; Child, Preschool ; Connective Tissue - drug effects ; Drug toxicity and drugs side effects treatment ; Eye Enucleation ; Eye Movements - drug effects ; Female ; Fibrosis ; Humans ; Infant ; Injections ; Male ; Medical sciences ; Ocular Motility Disorders - chemically induced ; Ophthalmology ; Orbit - pathology ; Pharmacology. Drug treatments ; Retinal Neoplasms - drug therapy ; Retinal Neoplasms - pathology ; Retinoblastoma - drug therapy ; Retinoblastoma - pathology ; Retinopathies ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the eye and orbit ; Toxicity: eye ; Treatment Failure</subject><ispartof>Archives of ophthalmology (1960), 2003-08, Vol.121 (8), p.1120-1124</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright American Medical Association Aug 2003</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a516t-441efb0528bb758f744589d043f431ce10ec133f4c7e4ea7165ada16fa2fd28e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15060311$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12912689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mulvihill, Alan</creatorcontrib><creatorcontrib>Budning, Andrew</creatorcontrib><creatorcontrib>Jay, Venita</creatorcontrib><creatorcontrib>Vandenhoven, Cynthia</creatorcontrib><creatorcontrib>Heon, Elise</creatorcontrib><creatorcontrib>Gallie, Brenda L</creatorcontrib><creatorcontrib>Chan, Helen S. L</creatorcontrib><title>Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma</title><title>Archives of ophthalmology (1960)</title><addtitle>Arch Ophthalmol</addtitle><description>BACKGROUND Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy. METHODS We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin. During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after tumor control with ocular motility at diagnosis. Eyes subsequently enucleated because of treatment failure (n = 4) were examined histologically. RESULTS Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy. Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis. The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult. Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.Arch Ophthalmol. 2003;121:1120-1124
--></description><subject>Adolescent</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - adverse effects</subject><subject>Child, Preschool</subject><subject>Connective Tissue - drug effects</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Eye Enucleation</subject><subject>Eye Movements - drug effects</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Humans</subject><subject>Infant</subject><subject>Injections</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Ocular Motility Disorders - chemically induced</subject><subject>Ophthalmology</subject><subject>Orbit - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Retinal Neoplasms - drug therapy</subject><subject>Retinal Neoplasms - pathology</subject><subject>Retinoblastoma - drug therapy</subject><subject>Retinoblastoma - pathology</subject><subject>Retinopathies</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the eye and orbit</subject><subject>Toxicity: eye</subject><subject>Treatment Failure</subject><issn>0003-9950</issn><issn>2168-6165</issn><issn>1538-3601</issn><issn>2168-6173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkFlLxDAQgIMouh4_QAQpgo9dMzm66aMsXqAIHs9h2k1spW1qkj7svzeyqz7N9c0MfIScAZ0DpXCFvm7c2MQ5MJirOQCjO2QGkqucFxR2yYxSyvOylPSAHIbwmcoCaLlPDoCVwApVzsjLcz116LMnF9uujets2eDwYUJ2baPx2etURTO4IVuir9zYYWxT3pjexcZ4HNeZdT57Mantqg5DdD0ekz2LXTAn23hE3m9v3pb3-ePz3cPy-jFHCUXMhQBjKyqZqqqFVHYhhFTligpuBYfaADU18FTUCyMMLqCQuEIoLDK7YsrwI3KxuTt69zWZEPWnm_yQXmrGoSykYCpBfAPV3oXgjdWjb3v0aw1U_2jUvxp10qiV_tGYts63p6eqN6v_na23BFxuAQw1dtbjULfhn5O0oBwgcacbDnv8mwqQUir-DWsVhaw</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>Mulvihill, Alan</creator><creator>Budning, Andrew</creator><creator>Jay, Venita</creator><creator>Vandenhoven, Cynthia</creator><creator>Heon, Elise</creator><creator>Gallie, Brenda L</creator><creator>Chan, Helen S. L</creator><general>American Medical Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20030801</creationdate><title>Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma</title><author>Mulvihill, Alan ; Budning, Andrew ; Jay, Venita ; Vandenhoven, Cynthia ; Heon, Elise ; Gallie, Brenda L ; Chan, Helen S. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a516t-441efb0528bb758f744589d043f431ce10ec133f4c7e4ea7165ada16fa2fd28e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - adverse effects</topic><topic>Child, Preschool</topic><topic>Connective Tissue - drug effects</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Eye Enucleation</topic><topic>Eye Movements - drug effects</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Humans</topic><topic>Infant</topic><topic>Injections</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Ocular Motility Disorders - chemically induced</topic><topic>Ophthalmology</topic><topic>Orbit - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Retinal Neoplasms - drug therapy</topic><topic>Retinal Neoplasms - pathology</topic><topic>Retinoblastoma - drug therapy</topic><topic>Retinoblastoma - pathology</topic><topic>Retinopathies</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the eye and orbit</topic><topic>Toxicity: eye</topic><topic>Treatment Failure</topic><toplevel>online_resources</toplevel><creatorcontrib>Mulvihill, Alan</creatorcontrib><creatorcontrib>Budning, Andrew</creatorcontrib><creatorcontrib>Jay, Venita</creatorcontrib><creatorcontrib>Vandenhoven, Cynthia</creatorcontrib><creatorcontrib>Heon, Elise</creatorcontrib><creatorcontrib>Gallie, Brenda L</creatorcontrib><creatorcontrib>Chan, Helen S. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Archives of ophthalmology (1960)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mulvihill, Alan</au><au>Budning, Andrew</au><au>Jay, Venita</au><au>Vandenhoven, Cynthia</au><au>Heon, Elise</au><au>Gallie, Brenda L</au><au>Chan, Helen S. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma</atitle><jtitle>Archives of ophthalmology (1960)</jtitle><addtitle>Arch Ophthalmol</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>121</volume><issue>8</issue><spage>1120</spage><epage>1124</epage><pages>1120-1124</pages><issn>0003-9950</issn><issn>2168-6165</issn><eissn>1538-3601</eissn><eissn>2168-6173</eissn><abstract>BACKGROUND Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy. METHODS We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin. During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after tumor control with ocular motility at diagnosis. Eyes subsequently enucleated because of treatment failure (n = 4) were examined histologically. RESULTS Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy. Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis. The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult. Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.Arch Ophthalmol. 2003;121:1120-1124
--></abstract><cop>Chicago, IL</cop><pub>American Medical Association</pub><pmid>12912689</pmid><doi>10.1001/archopht.121.8.1120</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9950 |
| ispartof | Archives of ophthalmology (1960), 2003-08, Vol.121 (8), p.1120-1124 |
| issn | 0003-9950 2168-6165 1538-3601 2168-6173 |
| language | eng |
| recordid | cdi_proquest_journals_231965428 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Carboplatin - administration & dosage Carboplatin - adverse effects Child, Preschool Connective Tissue - drug effects Drug toxicity and drugs side effects treatment Eye Enucleation Eye Movements - drug effects Female Fibrosis Humans Infant Injections Male Medical sciences Ocular Motility Disorders - chemically induced Ophthalmology Orbit - pathology Pharmacology. Drug treatments Retinal Neoplasms - drug therapy Retinal Neoplasms - pathology Retinoblastoma - drug therapy Retinoblastoma - pathology Retinopathies Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the eye and orbit Toxicity: eye Treatment Failure |
| title | Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T07%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20Motility%20Changes%20After%20Subtenon%20Carboplatin%20Chemotherapy%20for%20Retinoblastoma&rft.jtitle=Archives%20of%20ophthalmology%20(1960)&rft.au=Mulvihill,%20Alan&rft.date=2003-08-01&rft.volume=121&rft.issue=8&rft.spage=1120&rft.epage=1124&rft.pages=1120-1124&rft.issn=0003-9950&rft.eissn=1538-3601&rft_id=info:doi/10.1001/archopht.121.8.1120&rft_dat=%3Cproquest_cross%3E405723461%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=231965428&rft_id=info:pmid/12912689&rft_ama_id=415558&rfr_iscdi=true |